SNX2112

TargetMol
Product Code: TAR-T6305
Supplier: TargetMol
CodeSizePrice
TAR-T6305-1mg1mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-2mg2mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-5mg5mg£205.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-1mL1 mL * 10 mM (in DMSO)£217.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-10mg10mg£253.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-25mg25mg£381.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-50mg50mg£542.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-100mg100mg£744.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6305-500mg500mg£1,452.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
SNX-2112 is an orally active Hsp90 inhibitor, with a Kd of 16 nM.
CAS:
908112-43-6
Formula:
C23H27F3N4O3
Molecular Weight:
464.489
Pathway:
Metabolism; Cytoskeletal Signaling
Purity:
0.9995
SMILES:
CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1
Target:
HSP

References

Chinn DC, et al, Pediatr Blood Cancer, 2012, 58(6), 885-890. Chandarlapaty S, et al, Clin Cancer Res, 2008, 14(1), 240-248. Okawa Y, et al, Blood, 2009, 113(4), 846-855. Zhao D, Xu Y M, Cao L Q, et al. Complex Crystal Structure Determination and in vitro Anti?non?small Cell Lung Cancer Activity of Hsp90N Inhibitor SNX-2112. Frontiers in cell and developmental biology. 2021, 9: 567. Zhao D, Xu Y M, Cao L Q, et al. Complex Crystal Structure Determination and in vitro Anti?non?small Cell Lung Cancer Activity of Hsp90N Inhibitor SNX-2112. Frontiers in cell and developmental biology. 2021, 9: 567. Liu KS, et al, Cancer Lett, 2012, 318(2), 180-188.